（编辑 任世碧） 证券日报网讯 1月19日，沐曦股份在互动平台回答投资者提问时表示，受益于加速国产替代的行业趋 势，公司未来业务增长空间较大。从公司自身来看，凭借突出的技术优势和较强的产品竞争力，沐曦股 份产品已在人工智能下游各主要行业得到广泛应用，存量客户持续复购、新客户不断开拓，公司收入规 模呈快速增长，目前在手订单及潜在商机充足；公司以各类型算力底座客户为基本盘，同时大力开拓互 联网和运营商客户并已初见成效，未来亦将成为重要的业务增长极，提供发展动能。 ...

Investment Rating - The report gives a "Strong Buy" investment rating for the company [1][11]. Core Insights - The company is a leading domestic X-ray detector manufacturer, expected to benefit from a recovery in medical tenders and a resurgence in capital expenditure in the lithium battery sector, marking a turning point in its main business performance [2][8]. - The company is entering the high-growth AI glasses market through a partnership with Visionary Technology, which is anticipated to open new growth avenues [3][11]. Company Overview - The company is recognized as a leader in the domestic X-ray detector market, with a projected global market share of 20% by 2024 [18]. - It specializes in digital X-ray detectors, high-voltage generators, combination X-ray sources, and tubes, with applications spanning medical, industrial, and dental fields [18][19]. Main Business - The company is transitioning from a single supplier of X-ray detectors to a comprehensive supplier of X-ray solutions, enhancing product value and customer loyalty [8][27]. - Short-term recovery is expected due to improved downstream demand, with a projected revenue growth of 20% in 2025 [10][11]. - Long-term growth is driven by expanding product offerings, industry applications, and market penetration, with a focus on increasing overseas business, which is expected to account for 34% of revenue by mid-2025 [8][11]. New Business Ventures - The company is entering the high-growth AI glasses sector, leveraging its capabilities in OLED micro-displays through a partnership with Visionary Technology [3][9]. - The global XR device shipment is projected to grow significantly, with a CAGR of 55.5% from 2025 to 2029, indicating a robust market opportunity [8][11]. Financial Data and Valuation - Revenue projections for 2025, 2026, and 2027 are estimated at 22.01 billion, 34.56 billion, and 44.54 billion yuan, respectively, with corresponding net profits of 6.25 billion, 7.87 billion, and 10.08 billion yuan [10][11]. - The company maintains a strong financial position with a return on equity (ROE) of 9.0% and a debt-to-asset ratio of 46.4% [4].

明德生物（002932）(002932.SZ)公告，公司与交易对手方签署《关于蓝怡(湖南)医疗器械有限公司之收 购协议》，拟于首期收购中以增资及股权收购方式先行取得蓝怡(湖南)医疗器械有限公司(简称"湖南蓝 怡")51%股权，首期收购后湖南蓝怡成为公司控股子公司，纳入公司合并报表范围。若湖南蓝怡于2026 年度至2028年度相关经营情况满足《收购协议》约定的相关前置条件，公司将根据协议约定进一步收购 湖南蓝怡剩余股权，前述两阶段收购完成后，公司将合计持有湖南蓝怡100%股权。本次增资及股权收 购湖南蓝怡51%股权的交易作价合计为3570.10万元。 湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，在糖化血红蛋白检测方面掌握 高效液相色谱法(HPLC)，以AH-600系列糖化血红蛋白分析系统为核心相关检测产品凭借精准高效、权 威认证、成本可控等优势，成为国产替代与慢病管理的核心产品。 公告称，公司与标的公司核心业务分别覆盖急危重症与慢病管理，形成天然互补，共同覆盖院前急救、 院中诊断、院后随访及居家管理全流程，通过本次交易，公司将实现产业链的横向拓展，有利于公司构 建完整的产品生态，提升对 ...

湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，荣获国家级高新技术企业、专 精特新"小巨人"，在糖化血红蛋白检测方面掌握高效液相色谱法（HPLC），以AH-600系列糖化血红蛋 白分析系统为核心相关检测产品凭借精准高效、权威认证、成本可控等优势，成为国产替代与慢病管理 的核心产品。因前期产品研发投入较大，同时市场开拓期暂时性、战略性市场投入较高，湖南蓝怡目前 暂时亏损。随着国家将糖化血红蛋白纳入65岁及以上老人免费体检项目，基层医疗机构采购需求释放； 叠加海外业务持续增长，糖化业务将成为标的公司核心增长引擎，有望支撑其后续的业绩提升。 格隆汇1月19日丨明德生物(002932.SZ)公布，公司于2026年1月19日召开第五届董事会第三次会议，审 议并通过了《关于增资并收购蓝怡（湖南）医疗器械有限公司股权的议案》。同意在蓝怡科技集团股份 有限公司（简称"蓝怡集团"）与湖南蓝怡已完成历史债权债务的抵扣、转化或转移相关协议的签署的前 提下，公司首期以现金3,570.10万元，通过增资及股权收购方式取得蓝怡集团持有的湖南蓝怡51%股 权；同时蓝怡集团与嘉善禾欣咨询管理合伙企业（有限合伙）（简称" ...

湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，荣获国家级高新技术企业、专 精特新"小巨人"，在糖化血红蛋白检测方面掌握高效液相色谱法（HPLC），以AH-600系列糖化血红蛋 白分析系统为核心相关检测产品凭借精准高效、权威认证、成本可控等优势，成为国产替代与慢病管理 的核心产品。因前期产品研发投入较大，同时市场开拓期暂时性、战略性市场投入较高，湖南蓝怡目前 暂时亏损。随着国家将糖化血红蛋白纳入65岁及以上老人免费体检项目，基层医疗机构采购需求释放； 叠加海外业务持续增长，糖化业务将成为标的公司核心增长引擎，有望支撑其后续的业绩提升。 格隆汇1月19日丨明德生物(002932.SZ)公布，公司于2026年1月19日召开第五届董事会第三次会议，审 议并通过了《关于增资并收购蓝怡（湖南）医疗器械有限公司股权的议案》。同意在蓝怡科技集团股份 有限公司（简称"蓝怡集团"）与湖南蓝怡已完成历史债权债务的抵扣、转化或转移相关协议的签署的前 提下，公司首期以现金3,570.10万元，通过增资及股权收购方式取得蓝怡集团持有的湖南蓝怡51%股 权；同时蓝怡集团与嘉善禾欣咨询管理合伙企业（有限合伙）（简称" ...

同时，若湖南蓝怡于2026年度至2028年度相关经营情况满足《收购协议》约定的相关前置条件，公司将 根据协议约定进一步收购湖南蓝怡剩余股权，前述两阶段收购完成后，公司将合计持有湖南蓝怡100% 股权。 公告显示，湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，荣获国家级高新技 术企业、专精特新"小巨人"，在糖化血红蛋白检测方面掌握高效液相色谱法(HPLC)，以AH-600系列糖 化血红蛋白分析系统为核心相关检测产品凭借精准高效、权威认证、成本可控等优势，成为国产替代与 慢病管理的核心产品。 明德生物表示，因前期产品研发投入较大，同时市场开拓期暂时性、战略性市场投入较高，湖南蓝怡目 前暂时亏损。随着国家将糖化血红蛋白纳入65岁及以上老人免费体检项目，基层医疗机构采购需求释 放；叠加海外业务持续增长，糖化业务将成为标的公司核心增长引擎，有望支撑其后续的业绩提升。 北京商报讯(记者丁宁)1月19日晚间，明德生物（002932）发布公告称，公司拟于首期收购中以增资及 股权收购方式先行取得蓝怡(湖南)医疗器械有限公司(以下简称"湖南蓝怡")51%股权，首期收购后湖南 蓝怡成为公司控股子公司，纳入公 ...

湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与服务，荣获国家级高新技术企业、专 精特新"小巨人"，在糖化血红蛋白检测方面掌握高效液相色谱法(HPLC)，以AH-600系列糖化血红蛋白 分析系统为核心相关检测产品凭借精准高效、权威认证、成本可控等优势，成为国产替代与慢病管理的 核心产品。 人民财讯1月19日电，明德生物（002932）1月19日公告，公司与交易对手方签署《关于蓝怡(湖南)医疗 器械有限公司之收购协议》，拟于首期收购中以增资及股权收购方式先行取得蓝怡(湖南)医疗器械有限 公司(简称"湖南蓝怡")51%股权，首期收购后湖南蓝怡成为公司控股子公司。若湖南蓝怡于2026年度至 2028年度相关经营情况满足《收购协议》约定的相关前置条件，公司将根据协议约定进一步收购湖南蓝 怡剩余股权，前述两阶段收购完成后，公司将合计持有湖南蓝怡100%股权。经交易各方协商，本次增 资及股权收购湖南蓝怡51%股权的交易作价合计为3570.1万元。 ...

每经AI快讯，1月19日，明德生物（002932）(002932.SZ)公告称，公司与蓝怡科技集团股份有限公司签 署《关于蓝怡(湖南)医疗器械有限公司之收购协议》，拟以3570.10万元通过增资及股权收购方式取得蓝 怡(湖南)医疗器械有限公司51%股权。湖南蓝怡成立于2020年9月，核心聚焦IVD仪器、试剂研发生产与 服务，荣获国家级高新技术企业、专精特新"小巨人"，在糖化血红蛋白检测方面掌握高效液相色谱法 (HPLC)，以AH-600系列糖化血红蛋白分析系统为核心相关检测产品凭借精准高效、权威认证、成本可 控等优势，成为国产替代与慢病管理的核心产品。 ...

Investment Rating - The industry investment rating is "Overweight" [3] Core Insights - The chemical industry is experiencing a dual drive of cyclical recovery and growth, with a focus on organic silicon, PTA, polyester filament, caprolactam, spandex, vitamins, sweeteners, refrigerants, and phosphorus chemicals [6] - The organic silicon industry is entering a recovery phase, with new applications becoming the core growth engine. From 2019 to 2024, domestic DMC capacity expanded rapidly, leading to temporary oversupply and declining prices. However, by 2025, no new capacity is expected, and demand from emerging sectors like new energy vehicles and photovoltaics is growing, improving the supply-demand balance [6] - The PTA/polyester filament industry is seeing a reduction in capacity expansion, with future growth concentrated among leading companies. Domestic demand continues to grow, and external demand is improving due to easing trade tensions [7] - The refrigerant market is entering a high prosperity cycle, driven by quota policies and stable demand growth from markets like Southeast Asia [8] - Synthetic biology is at a pivotal moment, with low-energy products expected to gain a longer growth window as traditional chemical companies adapt to energy costs and carbon taxes [9] - OLED technology is accelerating its penetration into larger displays, supported by government policies promoting the new display industry [10] - The demand for high-frequency and low-loss resins is increasing due to the rise of AI infrastructure and new applications like low-orbit satellite communication [11] - Electronic chemicals are benefiting from the expansion of wafer production capacity, with increasing demand driven by the growth of the semiconductor industry [12] Summary by Sections Industry Performance - The chemical sector ranked 8th in overall performance for the week of January 12-16, 2026, with a gain of 0.90% [21] - The top-performing sub-sectors included coal chemicals and carbon black, while modified plastics and titanium dioxide saw declines [22] Company Performance - The top three gaining companies for the week were Qicai Chemical (27.94%), Aladdin (20.24%), and Xinjin Road (15.50%) [26] - The top three losing companies were Zaiseng Technology (-26.65%), ST Jiaao (-18.42%), and Pulite (-17.28%) [29] Industry Dynamics - The National Development and Reform Commission is implementing measures to support the circular economy, emphasizing the importance of solid waste management and resource recycling [35]

Core Viewpoint - The power semiconductor industry is entering a golden period driven by the boom in new energy vehicles and AI, with the Chinese market expected to exceed 180 billion yuan by 2025 [1]. Group 1: Company Overview - Changjing Technology, a leading power semiconductor company, has restarted its IPO process after more than two years, with the China Securities Regulatory Commission confirming its filing on January 15 [1]. - Established in 2018, Changjing Technology specializes in the R&D, production, and sales of semiconductor products, and has been recognized as one of China's top ten power semiconductor companies for six consecutive years [2]. - The company has built a complete industrial chain through acquisitions, including the purchase of Haide Semiconductor and the establishment of Changjing Pulian, enhancing its capabilities in wafer manufacturing [2]. Group 2: Financial Performance - According to its 2022 prospectus, Changjing Technology's revenue from 2020 to 2022 was 1.339 billion yuan, 1.902 billion yuan, and 1.884 billion yuan, respectively, with net profits of 66 million yuan, 244 million yuan, and 127 million yuan [3]. - Despite the acquisition of New Shunwei contributing to wafer revenue growth, the company's total revenue remained stable compared to 2021, while net profit saw a significant decline due to weak demand in the consumer electronics market and cyclical factors [3]. Group 3: Market Trends and Future Prospects - The power semiconductor industry is showing signs of recovery, with revenue growth entering an upward cycle since Q4 2022, creating a favorable external environment for companies [4]. - The global power semiconductor market is projected to grow from 411.5 billion yuan in 2020 to 610.1 billion yuan by 2025, with China's market expected to exceed 180 billion yuan [4]. - Changjing Technology is actively expanding into new application markets, particularly in automotive electronics, with over 3,500 AEC-Q certified automotive-grade products [5]. Group 4: Strategic Initiatives - The company plans to use the funds raised from its IPO to expand production capacity, including projects for an annual output of 8 billion new components and 600,000 6-inch power semiconductor chips [5]. - This expansion aims to enhance self-sufficiency in packaging and testing, reduce reliance on external foundries, and improve cost control and delivery capabilities [5]. Group 5: Shareholder Structure - The controlling shareholder of Changjing Technology is Shanghai Jianghao Enterprise Management Consulting Co., Ltd., which holds 6.9% of the shares and controls 31.62% of the voting rights [6]. - Notably, the company's shareholder list includes industry giants like Xiaomi and OPPO, highlighting its significant position in the consumer electronics supply chain [6].